Literature DB >> 26708045

Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.

Ewa Ruel1, Samantha Thomas2,3, Michaela A Dinan4,3, Jennifer M Perkins1, Sanziana A Roman5,6, Julie Ann Sosa4,7,3.   

Abstract

Cervical lymph node metastases are common in papillary thyroid cancer (PTC). Clinically negative lymph nodes confer uncertainty about true lymph node status, potentially prompting empiric postoperative radioactive iodine (RAI) administration even in low-risk patients. We examined the association of clinically (cN0) versus pathologically negative (pN0) lymph nodes with utilization of RAI for low-risk PTC. Using the National Cancer Database 1998-2011, adults with PTC who underwent total thyroidectomy for Stage I/II tumors 1-4 cm were evaluated for receipt of RAI based on cN0 versus pN0 status. Cut-point analysis was conducted to determine the number of pN0 nodes associated with the greatest decrease in the odds of receipt of RAI. Survival models and multivariate analyses predicting RAI use were conducted separately for all patients and patients <45 years. 64,980 patients met study criteria; 39,778 (61.2 %) were cN0 versus 25,202 (38.8 %) pN0. Patients with pN0 nodes were more likely to have negative surgical margins and multifocal disease (all p < 0.001). The mean negative nodes reported in surgical pathology specimens was 4; ≥5 pathologically negative lymph nodes provided the best cut-point associated with reduced RAI administration (OR 0.91, CI 0.85-0.97). After multivariable adjustment, pN0 patients with ≥5 nodes examined were less likely to receive RAI compared to cN0 patients across all ages (OR 0.89, p < 0.001) and for patients aged <45 years (0R 0.86, p = 0.001). Patients with <5 pN0 nodes did not differ in RAI use compared to cN0 controls. Unadjusted survival was improved for pN0 versus cN0 patients across all ages (p < 0.001), but not for patients <45 years (p = 0.11); adjusted survival for all ages did not differ (p = 0.13). Pathological confirmation of negative lymph nodes in patients with PTC appears to influence the decision to administer postoperative RAI if ≥5 negative lymph nodes are removed. It is possible that fewer excised lymph nodes may be viewed by clinicians as incidentally resected and thus may suboptimally represent the true nodal status of the central neck. Further research is warranted to determine if there is an optimal number of lymph nodes that should be resected to standardize pathological diagnosis.

Entities:  

Keywords:  Cervical lymph node metastasis; NCDB; Papillary thyroid cancer; Prophylactic lymph node dissection; Radioactive iodine

Mesh:

Substances:

Year:  2015        PMID: 26708045      PMCID: PMC4880494          DOI: 10.1007/s12020-015-0826-0

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  26 in total

1.  Radioiodine therapy in patients with stage I differentiated thyroid cancer.

Authors:  Jacqueline Jonklaas; David S Cooper; Kenneth B Ain; Thomas Bigos; James D Brierley; Bryan R Haugen; Paul W Ladenson; James Magner; Douglas S Ross; Monica C Skarulis; David L Steward; Harry R Maxon; Steven I Sherman
Journal:  Thyroid       Date:  2010-11-07       Impact factor: 6.568

2.  Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer.

Authors:  David T Hughes; Matthew L White; Barbra S Miller; Paul G Gauger; Richard E Burney; Gerard M Doherty
Journal:  Surgery       Date:  2010-12       Impact factor: 3.982

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma.

Authors:  Victor Zaydfudim; Irene D Feurer; Marie R Griffin; John E Phay
Journal:  Surgery       Date:  2008-12       Impact factor: 3.982

5.  Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma.

Authors:  Dana M Hartl; Elisabeth Mamelle; Isabelle Borget; Sophie Leboulleux; Haïtham Mirghani; Martin Schlumberger
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

6.  Consensus statement on the terminology and classification of central neck dissection for thyroid cancer.

Authors:  Sally E Carty; David S Cooper; Gerard M Doherty; Quan-Yang Duh; Richard T Kloos; Susan J Mandel; Gregory W Randolph; Brendan C Stack; David L Steward; David J Terris; Geoffrey B Thompson; Ralph P Tufano; R Michael Tuttle; Robert Udelsman
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

7.  A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer.

Authors:  Tracy S Wang; Kevin Cheung; Forough Farrokhyar; Sanziana A Roman; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

Review 8.  Using the NCDB for cancer care improvement: an introduction to available quality assessment tools.

Authors:  Mehul V Raval; Karl Y Bilimoria; Andrew K Stewart; David J Bentrem; Clifford Y Ko
Journal:  J Surg Oncol       Date:  2009-06-15       Impact factor: 3.454

9.  Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Koon Yat Wan; Chung Yau Lo
Journal:  Ann Surg Oncol       Date:  2011-06-17       Impact factor: 5.344

10.  The National Cancer Data Base: a powerful initiative to improve cancer care in the United States.

Authors:  Karl Y Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  Ann Surg Oncol       Date:  2008-01-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.